Introduction
============

Lung cancer continues to be a major health burden, with most cases diagnosed as non-small-cell lung cancer (NSCLC). This category includes nonsquamous (70%) and squamous (30%) histological subtypes.[@b1-ott-11-7691]--[@b3-ott-11-7691] Detection of early-stage NSCLC is often associated with a good prognosis.

However, the majority of patients have advanced, recurrent, or metastatic disease.[@b4-ott-11-7691] Prognosis for these patients is very poor. Although platinum-based doublet treatments are still approved as first-line treatment options for NSCLC,[@b5-ott-11-7691] cancer-associated, immune-targeted therapies have been shown to have survival benefit.[@b6-ott-11-7691],[@b7-ott-11-7691]

The PD-1 pathway inhibits immune responses, and it plays a critical role in many cancer types, including NSCLC. Different from chemotherapy, blockade of the PD-1 pathway can result in durable antitumor activity, significantly increasing long-term survival.[@b8-ott-11-7691]--[@b12-ott-11-7691]

Nivolumab (Opdivo^®^; Bristol-Myers Squibb, Princeton, NJ, USA), a PD-1 immune checkpoint inhibitor, was the first immune checkpoint inhibitor approved for metastatic NSCLC, for use after the failure of platinum-based chemotherapy.[@b13-ott-11-7691] The first trial was the CheckMate-017 trial,[@b14-ott-11-7691] in which nivolumab was shown to improve overall survival (OS), progression-free survival (PFS), and the overall response rate (ORR) over docetaxel. For the second trial, CheckMate-057 trial,[@b15-ott-11-7691] OS with nivolumab was less effective than docetaxel. For the CheckMate-026 trial,[@b16-ott-11-7691] survival efficacy with nivolumab was less than the investigator's choice chemotherapy.

In that effective management of NSCLC with nivolumab has been controversial and with conflicting results, the objective of this meta-analysis was to evaluate the oncological outcomes of nivolumab therapy in pretreated advanced NSCLC.

Materials and methods
=====================

Search strategy
---------------

PubMed, Embase, and Cochrane Library databases were searched up to June 2017 by two independent investigators with the following keywords: "non-small cell lung cancer," and "Programmed cell death-1," and "nivolumab." No limitation was used during the literature search. The references of eligible studies were hand-searched for additional studies.

Ethics Committee approval was waived because this study did not involve any human participants or animals.

Eligibility criteria
--------------------

Eligible studies for this meta-analysis met the following criteria: 1) the study was designed as a randomized control trial (RCT); 2) the study enrolled NSCLC patients treated with nivolumab and as well the investigator's choice chemotherapy; 3) outcomes of interest were efficacy (survival, tumor response), drug toxicity (incidence of severe adverse effects \[SAEs\]), and hazard ratios with 95% CIs were provided. Studies with the most complete outcomes data were included.

Quality assessment
------------------

The quality of the retrieved studies was rated independently by two of the authors. The risk of bias items recommended by *The Cochrane Handbook for Systematic Reviews of Interventions* were chosen.

Data extraction
---------------

Data were extracted by two authors independently. Disagreements were resolved by consensus. For each of the eligible studies, the main categories were based on the following: name of the first author, year of publication, study type, trial name, stage, histology, PD-L1 tumor expression level, treatment regimen, and endpoints of interest. Corresponding variables were adjusted and risk estimates of mortality with 95% CIs were assessed.

Statistical analysis
--------------------

The safety of anti-PD-1/PD-L1 was based on data from RCTs. The endpoints of interest for the pooled analyses were OS, PFS, ORR, and SAE data.

Sensitivity analysis, based on the heterogeneity between-studies, was examined using the *I* ^2^ statistic.[@b17-ott-11-7691] Studies with an *I* [@b2-ott-11-7691]≥50% were considered to have moderate to high heterogeneity, *I* [@b2-ott-11-7691]\<50% were considered to have low heterogeneity.[@b18-ott-11-7691] Summary hazard ratios were calculated by using fixed-effect models when there was low heterogeneity among the studies. Otherwise, random-effect models were used. A *P*-value \<0.05 was considered statistically significant. Statistical analyses were conducted using Review Manager Version 5.3 software (Revman; The Cochrane Collaboration, Oxford, UK). Meta-analyses are shown as forest plots. The Begg test and the Egger test were used to assess publication bias.

Results
=======

Overview of literature search and study characteristics
-------------------------------------------------------

By literature search, a total of 351 studies were identified. Of these, 13 studies were evaluated by reading the full article. Some of these studies did not report sufficiently detailed data and only three RCTs[@b14-ott-11-7691]--[@b16-ott-11-7691] met the criteria for inclusion. The search process is described in [Figure 1](#f1-ott-11-7691){ref-type="fig"}.

All included studies were based on moderate- to high-quality evidence. [Table 1](#t1-ott-11-7691){ref-type="table"} provides a brief description of the eligible studies, with some detail.

Clinical and methodological heterogeneity
-----------------------------------------

### Pooled analysis of PFS comparing the addition of nivolumab with chemotherapy

Pooling the PFS data from all three studies[@b14-ott-11-7691]--[@b16-ott-11-7691] showed that nivolumab did not lead to PFS benefit (odds ratio \[OR\]: 0.88, 95% CI: 0.64--1.20, *P*=0.41) compared with chemotherapy ([Figure 2](#f2-ott-11-7691){ref-type="fig"}).

### Pooled analysis of OS comparing the addition of nivolumab with chemotherapy

A random-effects model was used to pool the OS data,[@b14-ott-11-7691]--[@b16-ott-11-7691] since heterogeneity across the studies was significantly high. The pooled data showed that nivolumab plus chemotherapy did not improve OS (OR: 0.77, 95% CI: 0.57--1.03, *P*=0.08) over chemotherapy ([Figure 3](#f3-ott-11-7691){ref-type="fig"}).

### Pooled analysis of ORR comparing the addition of nivolumab with chemotherapy

Pooling ORR data[@b14-ott-11-7691]--[@b16-ott-11-7691] did not improve efficacy for nivolumab (OR: 1.40, 95% CI: 0.66--2.96, *P*=0.39). In other words, the addition of nivolumab did not increase the ORR ([Figure 4](#f4-ott-11-7691){ref-type="fig"}).

### Pooled analysis of SAEs comparing the addition of nivolumab with chemotherapy

SAE data were available for the three RCTs.[@b14-ott-11-7691]--[@b16-ott-11-7691] Results showed much worse (grade 3--5 adverse events) SAEs in the nivolumab group than in the chemotherapy group (OR: 0.13, 95% CI: 0.09--0.17, *P*\<0.00001) ([Figure 5](#f5-ott-11-7691){ref-type="fig"}). Subgroup meta-analysis of PFS and OS in patients with tumor PD-L1 expression levels ≥5% demonstrated that nivolumab therapy did not prolong PFS (OR: 0.84, 95% CI: 0.70--1.00, *P*=0.05) ([Figure 6](#f6-ott-11-7691){ref-type="fig"}) or OS (OR: 0.63, 95% CI: 0.34--1.15, *P*=0.13) ([Figure 7](#f7-ott-11-7691){ref-type="fig"}).

Discussion
==========

NSCLC is the main cause of cancer-related mortality worldwide.[@b5-ott-11-7691] Chemotherapy has provided modest improvements in the survival of patients with advanced NSCLC. Compared to traditional antineoplastic therapies, immune checkpoint receptors are able to target tumor cells and have been reported to be important in future cancer treatment.[@b19-ott-11-7691] PD-1 is a vital immune checkpoint receptor, which is expressed on activated T-cells[@b20-ott-11-7691] and has been demonstrated to be a valuable clinical target for cancer treatment. Based on results with nivolumab, anti-PD-1/PD-L1 therapy is a highly promising treatment for patients with advanced NSCLC. However, inconsistent results with nivolumab cannot be ignored.[@b14-ott-11-7691]--[@b16-ott-11-7691] Thus, this meta-analysis evaluated the efficacy and safety of nivolumab in advanced NSCLC patients.

In this analysis, the superiority of nivolumab therapy compared to chemotherapy for NSCLC patients was not found for OS, ORR, or PFS, even when limited to the PD-L1 ≥5% subpopulation. These results must be considered with caution. First, previous studies of nivolumab therapy for NSCLC included squamous and nonsquamous cell subtypes, and it has been shown that anti-PD-1/PD-L1 therapy may provide differential benefit for different histological subtypes. Data from the Cancer Genome Atlas Research Network showed that significant differences may be caused by the mutational complexity between adenocarcinoma and squamous cell lung cancers.[@b21-ott-11-7691],[@b22-ott-11-7691]

The majority of lung adenocarcinomas have undergone complex oncogene mutations, such as in the EGFR gene, ROS1 gene, and TKIs.[@b22-ott-11-7691] However, no similar driver mutations have been identified for squamous cell lung cancers.[@b21-ott-11-7691] As such, platinum-based doublet treatment has been accepted as first-line treatment for squamous NSCLC.[@b23-ott-11-7691] Second, for an individual patient, gene data-based analysis would provide a more precise estimate of the effect of nivolumab. The findings of this study may be due to a high rate of NSCLC harboring a K-ras-mutation. Subgroup analysis for the CheckMate-057 Trial[@b15-ott-11-7691] showed that patients with K-ras-mutations treated with nivolumab had a significant benefit in OS. Mechanistically, NSCLCs harboring K-ras mutations are associated with a higher mutational load and as such are more immunogenic. An increased mutational load may provide for increased efficacy of nivolumab in combination with carboplatin and paclitaxel due to the higher expression of PD-L1. Third, due to the heterogeneous nature of the included studies, bias may exist, and this may impact outcomes comparison. Pooled results are not optimal and may be questioned.

Early-stage trials have suggested that expression of PD-L1 on tumor cells or tumor-infiltrating lymphocytes (or both) may be worthwhile targets of the PD-1 pathway, serving as potential biomarkers,[@b24-ott-11-7691],[@b25-ott-11-7691] although the best cutoff scores have not been defined. Further trials are needed to determine the level of PD-L1 expression that provides maximal patient efficacy with a manageable nivolumab safety profile. However, in this analysis there was no difference among patients with PD-L1 expression level of ≥5% in OS or PFS.

The CheckMate-017 trial[@b14-ott-11-7691] demonstrated PD-L1 therapy to have no benefit for squamous NSCLC at any PD-L1 level. The CheckMate-057 trial[@b15-ott-11-7691] showed no significant benefit for nivolumab with regard to ORR, PFS, or OS for nonsquamous cell patients at different cut off scores, although there was a clear escalating clinical benefit with increasing PD-L1 expression levels.[@b26-ott-11-7691]

The tumor microenvironment is complicated. Colocalization of PD-L1 and tumor-infiltrating lymphocytes have been reported to be predictive of a protective antitumor response.[@b27-ott-11-7691] PD-L1 expression by other tumor-infiltrating immune cells can also affect a protective response.[@b28-ott-11-7691] Additional studies will be necessary to establish a relationship between PD-L1 expression and a patient's response to nivolumab treatment.

Immune-treatment adverse events are generally infrequent and less severe than other forms of cancer treatment. In this study, nivolumab showed comparatively few adverse events but did include pneumonitis, which was infrequent, of low severity, and acceptable by established guidelines. Overall, adverse events due to immunotherapies, such as nivolumab, differ from those seen with traditional cytotoxic drugs. Hence, such immunotherapies should be quickly advanced for rapid evaluation and the initiation of treatment.

Conclusion
==========

In conclusion, nivolumab monotherapy for patients with advanced NSCLC was generally well tolerated, with promising antitumor activity and a manageable safety profile.

More RCTs with larger sample sizes are needed to detect relevant biomarkers that have sufficient sensitivity and specificity to predict patient populations that would most benefit from nivolumab, in particular those patients with pretreated and advanced NSCLC.
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![Pooled analysis of PFS comparing the addition of nivolumab with chemotherapy.\
**Abbreviations:** OR, odds ratio; PFS, progression-free survival.](ott-11-7691Fig2){#f2-ott-11-7691}

![Pooled analysis of OS comparing the addition of nivolumab with chemotherapy.\
**Abbreviations:** OR, odds ratio; OS, overall survival.](ott-11-7691Fig3){#f3-ott-11-7691}

![Pooled analysis of ORR comparing the addition of nivolumab with chemotherapy.\
**Abbreviations:** OR, odds ratio; ORR, overall response rate.](ott-11-7691Fig4){#f4-ott-11-7691}

![Pooled analysis of SAEs comparing the addition of nivolumab with chemotherapy.\
**Abbreviations:** OR, odds ratio; SAE, serious adverse effect.](ott-11-7691Fig5){#f5-ott-11-7691}

![Subgroup meta-analysis of PFS among patients with PD-L1 expression level of ≥5%.\
**Abbreviations:** OR, odds ratio; PFS, progression-free survival.](ott-11-7691Fig6){#f6-ott-11-7691}

![Subgroup meta-analysis of OS among patients with PD-L1 expression level of ≥5%.\
**Abbreviations:** OR, odds ratio; OS, overall survival.](ott-11-7691Fig7){#f7-ott-11-7691}

###### 

The primary characteristics of the eligible studies in more detail

  Study                              Year   Trial name      Trial phase   Stage             Histology                  PD-L1 tumor expression level   Study arm (N)                             Comparative arm (N)
  ---------------------------------- ------ --------------- ------------- ----------------- -------------------------- ------------------------------ ----------------------------------------- ----------------------------------------------------------------------
  Brahmer et al[@b15-ott-11-7691]    2015   CheckMate 017   3             IIIb/IV           Squamous                   ≥1%, ≥5%, and ≥10%             Nivolumab 3 mg/kg every 2 weeks (n=135)   Docetaxel 75 mg/m^2^ every 3 weeks (n=137)
  Borghaei et al[@b14-ott-11-7691]   2015   CheckMate 057   3             IIIb/IV           Nonsquamous                ≥1%, ≥5%, and ≥10%             Nivolumab 3 mg/kg every 2 weeks (n=292)   Docetaxel 75 mg/m^2^ every 3 weeks (n=290)
  Carbone et al[@b16-ott-11-7691]    2017   CheckMate 026   3             IV or recurrent   Squamous and nonsquamous   ≥1% and ≥5%                    Nivolumab 3 mg/kg every 2 weeks (n=271)   Investigator's choice of platinum-based doublet chemotherapy (n=270)
